News (Updated June 22,
2003)
[Home]
[Previous
news]
|
Fri Jun 20, 2:57 AM ET
|
NEW YORK (Reuters Health) - Public health experts estimate that roughly three percent of Beijing's gay and bisexual male population is infected with HIV, according to a new report.
"Our data suggest that there is low but significant HIV-1 prevalence in men who have sex with men in Beijing," the authors write in the June 21st issue of The Lancet.
"However, in view of high rates of unprotected sex in such men, HIV-infection rates will continue to rise unless prevention measures are implemented," they add.
Few studies have been conducted in China to determine the prevalence of HIV infection among gay and bisexual men, according to the report.
Since experts estimate that between 2 and 8 million Chinese men have sexual relations with men, many believe that HIV infection rates in this population could play an important role in the spread of the virus.
In the current study, Dr. Kyung-Hee Choi of the University of California, San Francisco and colleagues interviewed 481 men in Beijing who said they had sex with men. All of the men also got an HIV test.
Of the group, 15 men, or 3.1 percent, were infected with HIV, and nearly half of the group noted that they had had unprotected anal sex with a man in the previous six months, and 22 percent had unprotected anal or vaginal sex with a woman during that same time.
In addition, the researchers found that men older than 39 were 4.5 times more likely to be infected with the virus compared with younger men. Since older men were much more likely to have been married, the authors express concern that these men may "contribute to the sexual transmission of HIV to heterosexually active adults."
"Efforts are urgently needed to prevent further spread of infection both in these men and to their heterosexual partners," the authors conclude.
The United Nations estimates that between 800,000 and 1.5 million people in China were infected with HIV at the end of 2001, and the number could grow to 10 million by 2010 if swift action to control the spread of the disease is not taken.
SOURCE: The Lancet 2003;361:2125-2126.
|
Wed Jun 18, 6:08 PM ET
|
By Charnicia E. Huggins
NEW YORK (Reuters Health) - Although one in
three new cases of HIV in the U.S. occur among women, many women feel too
embarrassed to discuss sexually transmitted diseases (STDs) with their doctors
or sex partners, new survey findings show.
This "sexual silence" can lead to ignorance about sexual health
issues, Dr. Hilda Hutcherson, of Columbia University in New York, said during a
Tuesday media briefing jointly held by the survey sponsors, the Henry J. Kaiser
Family Foundation and SELF magazine.
Indeed, more than 80 percent of the 800 women surveyed did not know that one
third of new HIV cases occur among women, or that one quarter of Americans are
likely to get an STD -- many of which are symptomless -- at some point in their
life.
Sixty percent of the 18 to 49 year-olds surveyed were also unaware that women
are more susceptible to STDs than men and up to 65 percent did not know that an
STD can lead to liver damage and an increased risk for HIV or cancer. Most women
were aware that STDs can also lead to infertility and pregnancy complications.
Currently, an estimated 65 million people in the U.S. are living with an
incurable sexually transmitted disease, and approximately 15 million men and
women in the U.S. develop a new STD each year, experts say.
Still, about half of women in the U.S. have never discussed HIV/AIDS or any
other STD with their doctor, according to the survey. Fifteen percent say they
have deliberately withheld information about their sexual health from their
doctors, and 14 percent said their doctor didn't need to know such information.
In her current practice as a gynecologist, Hutcherson said the most common
reasons her patients give for their lack of communication about sexual health
issues are embarrassment, guilt and shame.
The same was true of the women surveyed. Nearly 90 percent said they were
embarrassed to discuss sexual health issues with their partner, and a similar
proportion said they worried what their partner would think of them. Sixty-nine
percent said their partner didn't need to know and almost half said they
believed women shouldn't talk about such things.
Some women fear their partners may think they're promiscuous, Hutcherson
said, citing the example of one woman who said, "he might think I've been
around the block a few times."
But the "truth of the matter" is that women can die from their lack
of knowledge about STDs, Hutcherson said.
Dr. Vanessa Cullins, also present during the briefing, added that women --
and their doctors who may also feel uncomfortable discussing sexual health
issues -- need to get past their feelings of embarrassment so they can take
charge of their "reproductive destiny." Cullins is vice president of
medical affairs for Planned Parenthood Federation of America.
In other findings, up to 64 percent of women said they had ever been tested
for HIV or other STDs. However, 15 percent to 20 percent incorrectly believed
that such testing was a routine part of their gynecological examination.
For example, 40 percent of women surveyed said the Pap smear, which tests for
abnormal cells that can lead to cervical cancer, also tests for STDs, and nearly
10 percent believed it was a test for HIV/AIDS or pregnancy. Cervical cancer is
usually caused by the sexually transmitted human papillomavirus (HPV), but the
Pap smear does not directly test for the virus.
In general, Cullins said, doctors do not conduct a battery of STD tests on
their patients. She added that women should help guide their doctors, by telling
them if they think they should be tested for a few different STDs.
What it all boils down to, Hutcherson said, is the "individual
responsibility of each woman." They need to demand answers from their
doctors and demand proper treatment, she said.
The Kaiser Family Foundation/Self National Survey of Women on their Sexual
Health was conducted via telephone from December 10, 2002 until January 19,
2003. The margin of error is plus or minus 3.6 percent and may be larger in some
subsets of women included in the survey.
Laurence Gibson, Positive Nation
SUMMARY: Researchers studying the reasons why HIV-positive people smoke
marijuana found that more patients smoke for mental rather than physical
reasons.
Clinical research studying the reasons why HIV-positive people smoke
marijuana has come up with some surprising results: More smoke for mental rather
than physical reasons.
The research, from the San Mateo Medical Center in California, was presented
last month at the American Psychiatric Association conference.
"We expected to see people smoking marijuana to alleviate nausea, pain
and to increase their appetite -- all the reasons that are commonly cited,"
said Diane Prentiss, a research epidemiologist with the center. "In this
case, we were surprised that 57 percent say they smoked to relieve anxiety or
depression."
The researchers surveyed 252 HIV patients. From that number, 23 percent, or
58 patients, admitted to smoking pot in the previous four weeks.
When asked for the main reasons why they used the drug, respondents cited
mental health issues most often. Curbing nausea and increasing appetite was the
second, with 52 percent. Recreational use came in third with 33 percent,
followed by pain relief with 28 percent.
The findings raise some interesting questions, said Dr. Dennis Israelski,
chief research officer at the Medical Center.
"In terms of understanding the whole field, it is safe to say that there
is a fair amount of self-medication that physicians are not aware of," he
told the San Francisco Examiner. "It does speak to whether it's appropriate
medication. Are physicians doing a good enough job when patients are using
outside medication? Do we have better treatments for anxiety and depression?
These are very important issues related to quality of life."
Israelski noted that, according to various studies, mental health often
influences a patient's ability to adhere to the strict therapeutic regimens for
HIV/AIDS.
He added that more scientific studies about marijuana's effects are
necessary, but the drug's illegal status has hampered research.
JOHANNESBURG (AFP) - South Africa will soon launch the first trial of a
vaccine against the HIV strain which predominates in southern Africa, the
epicentre of the world AIDS pandemic.
The Medicines Control Council (MCC) has approved the first phase of a human
trial to test the safety and side-effects of a prototype vaccine against HIV's
subtype C, the South African AIDS Vaccine Initiative and HIV Vaccine Trials
Network said in a statement Thursday.
"The C-strain of HIV occurs in southern Africa and it is the first time
that a vaccine specifically developed for this strain goes into trial,"
principal trial investigator Glenda Gray told AFP.
About 15 million people with HIV live in southern Africa, according to 2001
figures supplied by the UN agency UNAIDS.
The trials will be conducted in conjunction with the United States where the
so-called "alpha-virus replicon vector" technology, the basis for
these trials, was developed.
The technology involves using parts of another virus, in this case the South
American horse virus (VEE), to deliver the vaccine to the body's immune cells.
The VEE has been altered so that, even though technically it infects the
trial volunteers, it cannot do them any harm, Gray said.
Some 96 HIV-negative volunteers will be injected with the vaccine which
contains VEE, tucked inside of which is a small section of genetic material from
HIV.
It does not include the genetic elements needed to reconstitute live HIV --
just enough, hopefully, to prime the immune system so that it recognises and
attack the virus should it ever enter the body.
"There is no possibility of the vaccine itself causing HIV
infection," Gray said.
The trials are scheduled to start in the United States next month. If the
initial safety data is satisfactory, the South African trials will start in
August and will take about two years.
"The United States felt comfortable with going first for several reasons
... there is the issue around using guinea pigs, especially in developing
countries," Gray said.
If the vaccine is successful, it could be on the shelves within the next 10
years.
The human immunodeficiency virus (HIV) is a variable and highly mutating
virus for which no cure or vaccine exists.
Its main class, HIV-1, has two groups, group M and group O.
Within group M there are currently known to be at least 10 genetically
distinct subtypes of HIV-1. These are subtypes A to J.
The main subtypes are B, mostly found in the Americas, Japan, Australia, the
Caribbean and Europe; A and D, which predominate in sub-Saharan Africa; C, which
prevails in southern Africa and India; and E, found in Central African Republic,
Thailand and other countries of southeast Asia.
Vaccines have to undergo three phases of human trials, using ever-larger
groups of volunteers, to make sure they are safe and effective. This is why the
testing process is so long and expensive.
WASHINGTON - The government has approved the first once-a-day protease
inhibitor to treat the AIDS virus.
Protease inhibitors are a powerful type of drug that revolutionized HIV care
in the mid-1990s. While they're not a cure, protease inhibitors taken together
with older AIDS medicines suppress HIV enough to allow many patients to stay far
healthier for years longer.
But these so-called drug cocktails require swallowing handfuls of pills
several times a day.
The newest protease inhibitor, Reyataz, requires just a once-daily dose of
two pills, taken with food — plus whatever older medications patients take as
part of their daily cocktail.
Six other protease inhibitors already are sold, but require taking several
pills two or three times a day.
The Food and Drug Administration approved use of Reyataz as part of
combination HIV therapy on Friday. Manufacturer Bristol-Myers Squibb said the
drug, known chemically as atazanavir, would hit pharmacy shelves next month. The
company refused to reveal the price, saying only that it would be competitive
with other protease inhibitors.
Reyataz appears to work as well as other protease inhibitors. But a common
side effect of other protease inhibitors is a rise in cholesterol — and for
some reason, Reyataz so far doesn't appear to cause that problem, the FDA said.
However, up to 24 percent of Reyataz patients can experience jaundice, a
yellowing of the skin or eyes. It seems to quit when patients stop taking the
drug, and doesn't appear to be associated with liver injury, the FDA said.
Other side effects include nausea, infection, headache and diarrhea.
(HealthDay is the new name for HealthScoutNews.) FRIDAY, June 20 (HealthDayNews) -- Half of HIV-infected Americans use
alternative medicine along with, or in place of, antiretroviral drugs, but
doctors often aren't aware of what their patients are doing and therefore can't
warn them about potential adverse interactions That's the finding of a University of California, Los Angeles/RAND study in
the June 19 issue of the Journal of AIDS . About a quarter of HIV-patients use alternative medicine that may interact
with their conventional therapy, but don't tell their doctors about it, the
study found. That emphasizes the need for doctors to openly discuss alternative
medicine practices with their HIV patients. "Antiretroviral drugs can help people with AIDS enjoy longer and
healthier lives, but these medicines are expensive, can be hard to take and some
may cause serious side effects," researcher Dr. An-Fu Hsiao says in a news
release. "Alternative medicine can ease antiretroviral drugs' side effects, but
also create its own set of problems. Our findings illustrate why it's essential
for doctors to discuss alternative medicine use with their patients." Hsiao and his fellow researchers collected data through a follow-up survey of
2,466 HIV-positive adults who took part in the HIV Cost and Services Utilization
Study. The UCLA/RAND study found that 53 percent of the study subjects used some
form of alternative medicine and 26 percent didn't discuss their alternative
medicine use with their doctors. The study also found that 26 percent used potentially harmful alternative
medicine methods, such as megavitamin doses, homeopathy and the unlicensed use
of prescription drugs not designed to treat HIV/AIDS. Of these patients, 15 percent used herbs and 13 percent took megavitamin
doses. Three percent of the people in the study substituted alternative medicine for
antiretroviral therapy. More than half of this group didn't discuss it with
their doctors. People who believed the risks of antiretroviral therapy were not worth taking
were eight times more likely to substitute alternative therapy for
antiretroviral treatment. The study also found people who had a strong desire to
be involved in the medical decision-making for their HIV treatment were more
likely to use alternative therapy and more likely to substitute it for
antiretroviral therapy. "This is a wake-up call for physicians to ask their patients about
alternative medicine use. Twenty-six percent of these HIV patients used a form
of alternative medicine that could adversely interact with conventional
treatment. Yet one-third of their doctors had no idea," Hsiao says.
June 13, 2003
By DONALD G. McNEIL Jr.
They believe the simian precursor to the AIDS virus was
created in chimps that ate two kinds of monkeys withThey made the deduction by sequencing the genes of the
simian immunodeficiency viruses in chimpanzees and 30The study, done jointly by researchers at the University of
Nottingham, the University of Alabama at Birmingham, Duke University, Tulane University and the University of Montpellier in France, appears today in the journalThe conclusion is important, said Dr. Beatrice Hahn, a
University of Alabama at Birmingham virologist and one ofUnlike the other great apes, chimpanzees are formidable
hunters. Troops of males often work together; some chaseHunting males tear their catches limb from limb and eat
them on the spot, share the carcasses or trade them toThe prevailing theory about the origin of H.I.V. is that
somewhere in central Africa, probably between 1910 andHowever, "a lot of people just don't buy this and say it
was polio vaccine or dirty needles or tattooing or crazyExperts not connected with the study said they found it
plausible. Dr. Ronald Desrosiers, a professor of geneticsAnother expert, Edward Hooper, argued in a 1999 book,
(Little, Brown), that a chimpanzee virus passed into humans when an experimental oral polio vaccine was grown in a medium containing chimpanzee cells and used in parts of the former Belgian Congo in 1957 to 1960. He called the study "reasonably plausible, though based on limited data.""I have no problem with the idea that chimps got it by
eating other monkeys," he said.Scientists believe two monkey viruses were involved because
the virus from guenons (Cercopithecus nictitans) wasThere is no way to know when the two viruses merged inside
one chimpanzee. "It could have been hundreds of years ago or tens of thousands of years ago," Dr. Hahn said.Chimp virus has been found in two subspecies found in
central Africa known as troglodytes and schweinfurthii, butThe virus's failure to spread to all chimpanzees before
they diversified into subspecies suggests that it isA related study of the virus in wild chimpanzees by many of
the same authors, scheduled to appear in the Journal ofBy contrast, 50 to 90 percent of most adult monkeys are
infected with their versions, said Dr. Paul M. Sharp, aBecause wild chimpanzees, which grow nearly six feet tall,
can easily kill humans, getting blood samples is dangerous, so researchers watch chimps closely enough to be able to test their feces and urine.It is still unclear exactly how chimpanzees infect each
other and why the disease isn't more rampant among them,Nursing is surely one route, Dr. Hahn said, because some
chimps captured in infancy are infected.